<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Anavex Life Sciences Corp — News on 6ix</title>
<link>https://6ix.com/company/anavex-life-sciences-corp</link>
<description>Latest news and press releases for Anavex Life Sciences Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/anavex-life-sciences-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354a3978dffbe2df0e4963.webp</url>
<title>Anavex Life Sciences Corp</title>
<link>https://6ix.com/company/anavex-life-sciences-corp</link>
</image>
<item>
<title>Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-highlights-new-scientific-findings-on-shared-biology-between-autism-and-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-highlights-new-scientific-findings-on-shared-biology-between-autism-and-alzheimers-disease</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy</description>
</item>
<item>
<title>Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 07 Apr 2026 11:30:00 GMT</pubDate>
<description>NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 25th Annual Needham Virtual Healthcare Conference, April 13</description>
</item>
<item>
<title>Anavex Life Sciences Provides Comprehensive Regulatory Update</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-provides-comprehensive-regulatory-update</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-provides-comprehensive-regulatory-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data</description>
</item>
<item>
<title>Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-presents-new-data-from-its-ad-004-phase-iibiii-trial-at-adpd-2026-conference-demonstrating-consistent-correlation-between-the-treatment-effect-of-oral-blarcamesine-and-preservation-of-brain-volume-in-early-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-presents-new-data-from-its-ad-004-phase-iibiii-trial-at-adpd-2026-conference-demonstrating-consistent-correlation-between-the-treatment-effect-of-oral-blarcamesine-and-preservation-of-brain-volume-in-early-alzheimers-disease</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral</description>
</item>
<item>
<title>Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-presents-significant-treatment-effects-of-blarcamesine-in-new-advanced-alpha-synuclein-model-of-parkinsons-disease-at-adpd-2026-conference</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-presents-significant-treatment-effects-of-blarcamesine-in-new-advanced-alpha-synuclein-model-of-parkinsons-disease-at-adpd-2026-conference</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer'</description>
</item>
<item>
<title>Anavex Life Sciences to Present at the Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-to-present-at-the-citizens-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-to-present-at-the-citizens-life-sciences-conference</guid>
<pubDate>Tue, 03 Mar 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at</description>
</item>
<item>
<title>Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-to-present-at-the-46th-td-cowen-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-to-present-at-the-46th-td-cowen-annual-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at t</description>
</item>
<item>
<title>Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-appoints-seasoned-healthcare-leader-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-appoints-seasoned-healthcare-leader-to-board-of-directors</guid>
<pubDate>Mon, 23 Feb 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. “We are deli</description>
</item>
<item>
<title>Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-reports-fiscal-123000235</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-reports-fiscal-123000235</guid>
<pubDate>Mon, 09 Feb 2026 12:30:00 GMT</pubDate>
<description>Company to host a webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its first q</description>
</item>
<item>
<title>Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-announce-fiscal-123000287</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-announce-fiscal-123000287</guid>
<pubDate>Tue, 03 Feb 2026 12:30:00 GMT</pubDate>
<description>Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ETNEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will</description>
</item>
<item>
<title>Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-joins-access-ad-major-123000242</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-joins-access-ad-major-123000242</guid>
<pubDate>Tue, 13 Jan 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer’s disease (AD) across real-world clinical settings. The five year program is funded by the European Commission’s Innovative Health Initiative (IHI) and unites leading academic c</description>
</item>
<item>
<title>Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-appoints-senior-123000442</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-appoints-senior-123000442</guid>
<pubDate>Thu, 08 Jan 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Ne</description>
</item>
<item>
<title>Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-receives-fda-123000259</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-receives-fda-123000259</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company...</description>
</item>
<item>
<title>Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-submitted-request-ema-re-examine-its-opinion-2025-12-18</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-submitted-request-ema-re-examine-its-opinion-2025-12-18</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-provides-update-regulatory-review-eu-blarcamesine-treat-early</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-provides-update-regulatory-review-eu-blarcamesine-treat-early</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-present-oral-blarcamesine-data-18th-clinical-trials-alzheimers</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-present-oral-blarcamesine-data-18th-clinical-trials-alzheimers</guid>
<pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
<description>One Oral Late Breaking Communication and Two Poster Presentations NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the</description>
</item>
<item>
<title>Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)</description>
</item>
<item>
<title>Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-present-44th-annual-jp-morgan-healthcare-conference-2025-11-19</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-present-44th-annual-jp-morgan-healthcare-conference-2025-11-19</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-announce-fiscal-2025-fourth-quarter-financial-results-tuesday</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-announce-fiscal-2025-fourth-quarter-financial-results-tuesday</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex”</description>
</item>
<item>
<title>Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease</title>
<link>https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-provides-regulatory-update-blarcamesine-early-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/anavex-life-sciences-corp/news/anavex-life-sciences-provides-regulatory-update-blarcamesine-early-alzheimers-disease</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s</description>
</item>
</channel>
</rss>